Drug name - Rhopressa
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8450344 | AERIE PHARMS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(3 years from now) | |
| US9096569 | AERIE PHARMS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(3 years from now) | |
| US10654844 | AERIE PHARMS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(7 years from now) | |
| US10174017 | AERIE PHARMS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(7 years from now) | |
| US8394826 | AERIE PHARMS INC | Dual mechanism inhibitors for the treatment of disease |
Nov, 2030
(8 years from now) | |
| US9415043 | AERIE PHARMS INC | Combination therapy |
Mar, 2034
(11 years from now) | |
| US10588901 | AERIE PHARMS INC | Combination therapy |
Mar, 2034
(11 years from now) | |
| US9931336 | AERIE PHARMS INC | Combination therapy |
Mar, 2034
(11 years from now) | |
| CN105263494A | AERIE PHARMS INC | Combination Therapy |
Aug, 2020
(2 years ago) | |
| CN109528721A | AERIE PHARMS INC | Combination Therapy |
Mar, 2034
(11 years from now) | |
| CN109528721B | AERIE PHARMS INC | Combination Therapy |
Mar, 2034
(11 years from now) | |
| EP2326623A2 | AERIE PHARMS INC | Beta-And Gamma-Amino-Isoquinoline Amide Compounds And Substituted Benzamide Compounds |
Jul, 2029
(6 years from now) | |
| EP2326623B1 | AERIE PHARMS INC | Beta-And Gamma-Amino-Isoquinoline Amide Compounds And Substituted Benzamide Compounds |
Jul, 2029
(6 years from now) | |
| EP2424842B1 | AERIE PHARMS INC | Dual Mechanism Inhibitors For The Treatment Of Disease |
Jan, 2030
(7 years from now) | |
| EP3354643A1 | AERIE PHARMS INC | Dual Mechanism Inhibitors For The Treatment Of Disease |
Jan, 2030
(7 years from now) | |
| EP3354643B1 | AERIE PHARMS INC | Dual Mechanism Inhibitors For The Treatment Of Disease |
Jan, 2030
(7 years from now) | |
| EP2424842A2 | AERIE PHARMS INC | Dual Mechanism Inhibitors For The Treatment Of Disease |
Jan, 2030
(7 years from now) | |
| EP3053913A1 | AERIE PHARMS INC | Dual Mechanism Inhibitors For The Treatment Of Disease |
Jan, 2030
(7 years from now) | |
| EP3053913B1 | AERIE PHARMS INC | Dual Mechanism Inhibitors For The Treatment Of Disease |
Jan, 2030
(7 years from now) | |
| EP2976080A1 | AERIE PHARMS INC | Conjugates Of Isoquinoline Compounds And Prostaglandins |
Mar, 2034
(11 years from now) | |
| EP2976080B1 | AERIE PHARMS INC | Conjugates Of Isoquinoline Compounds And Prostaglandins |
Mar, 2034
(11 years from now) | |
| EP3461484B1 | AERIE PHARMS INC | Dimesylate Salts Of 4-(3-Amino-1-(Isoquinolin-6-Ylamino)-1-Oxopropan-2-Yl)Benzyl, Their Combinations With Prostaglandins And The Use Thereof In The Treatment Of Ocular Disorders |
Mar, 2034
(11 years from now) | |
| EP3461484A1 | AERIE PHARMS INC | Dimesylate Salts Of 4-(3-Amino-1-(Isoquinolin-6-Ylamino)-1-Oxopropan-2-Yl)Benzyl, Their Combinations With Prostaglandins And The Use Thereof In The Treatment Of Ocular Disorders |
Mar, 2034
(11 years from now) | |
| EP3461484B9 | AERIE PHARMS INC | Dimesylate Salts Of 4-(3-Amino-1-(Isoquinolin-6-Ylamino)-1-Oxopropan-2-Yl)Benzyl, Their Combinations With Prostaglandins And The Use Thereof In The Treatment Of Ocular Disorders |
Mar, 2034
(11 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10882840 | AERIE PHARMS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(3 years from now) | |
| US10532993 | AERIE PHARMS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(3 years from now) | |
| US11021456 | AERIE PHARMS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(3 years from now) | |
| US11028081 | AERIE PHARMS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(7 years from now) | |
| US11185538 | AERIE PHARMS INC | Compositions for treating glaucoma or reducing intraocular pressure |
Mar, 2034
(11 years from now) | |
Drugs and Companies using NETARSUDIL MESYLATE ingredient
Treatment: Reduction of elevated intraocular pressure
Dosage: SOLUTION/DROPS;OPHTHALMIC
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 0.02% BASE | SOLUTION/DROPS;OPHTHALMIC | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.